Tumor Biology

, Volume 37, Issue 1, pp 473–478 | Cite as

RETRACTED ARTICLE: Down-regulation of Sphk2 suppresses bladder cancer progression

  • Erlin Sun
  • Wenbo Zhang
  • Lining Wang
  • Aixiang Wang
  • Chengquan Ma
  • Mingde Lei
  • Xiaodong Zhou
  • Yan Sun
  • Bingxin Lu
  • Liwei Liu
  • Ruifa Han
Original Articles

Abstract

Bladder cancer is the second most common urological malignancy around the world and is by far the most frequent urological malignancy in China. The abnormal expression of sphingosine kinase 2 (SphK2) is associated with tumor progression and a poor patient survival rate, however, the effect of SphK2 on the bladder cancer cells remains unclear. The aim of the paper was to study the expression of SphK2 in bladder cancer and the role of SphK2 on the cell proliferation, metastasis, and apoptosis in bladder cancer in vitro. Our results showed that SphK2 is up-regulated in bladder cancer tissues compared with the corresponding adjacent non-neoplastic tissues, and the expression level of SphK2 was significantly higher in human bladder cancer cells in comparison with normal bladder epithelial cells. Silencing of SphK2 could inhibit the proliferation ability of T24 cells in vitro. In addition, SphK2 knockdown could induce a significant increase in the number of apoptotic cells. Furthermore, the transwell assay also showed significant cell migration inhibition in SphK2 siRNA transfectant compared with cell lines transfected with NC. Thus, this study suggested that SphK2 inhibition may provide a promising treatment for bladder cancer patients.

Keyword

SphK2 Bladder cancer Apoptosis Proliferation Migration 

Notes

Acknowledgments

This work is supported by the National Natural Science Foundation of China, 81402095; and the Science and Technology Foundation of Tianjin Public Health Bureau, 2013KZ110

Conflicts of interest

None

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Suriano F, Altobelli E, Sergi F, Buscarini M. Bladder cancer after radiotherapy for prostate cancer. Rev Urol. 2013;15:108–12.PubMedPubMedCentralGoogle Scholar
  3. 3.
    von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Shirodkar SP, Lokeshwar VB. Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol. 2009;19:488–49.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets. 2008;9:662–73.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Oskeritzian CA, Alvarez SE, Hait NC, Price MM, Milstien S, Spiegel S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood. 2008;111:4193–200.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S. Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol. 2002;71:493–511.CrossRefPubMedGoogle Scholar
  10. 10.
    Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106:57–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Miller AV, Alvarez SE, Spiegel S, Lebman DA. Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells. Mol Cell Biol. 2008;28:4142–51.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gao P, Smith CD. Ablation of sphingosine kinase-2 inhibits tumor ell proliferation and migration. Mol Cancer Res. 2011;9:1509–19.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010;333:129–39.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gestaut MM, Antoon JM, Burow ME, Beckman BS. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacol Rep. 2014;66:174–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005;64:695–705.CrossRefPubMedGoogle Scholar
  16. 16.
    Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem. 2003;278:46832–9.CrossRefPubMedGoogle Scholar
  17. 17.
    French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003;63:5962–9.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Erlin Sun
    • 1
  • Wenbo Zhang
    • 2
  • Lining Wang
    • 1
  • Aixiang Wang
    • 1
  • Chengquan Ma
    • 1
  • Mingde Lei
    • 1
  • Xiaodong Zhou
    • 1
  • Yan Sun
    • 1
  • Bingxin Lu
    • 1
  • Liwei Liu
    • 1
  • Ruifa Han
    • 1
  1. 1.Department of Urology, Tianjin Institute of UrologyThe 2nd Hospital of Tianjin Medical UniversityTianjinChina
  2. 2.School of life Sciences and TechnologyXinxiang Medical UniversityXinxiangChina

Personalised recommendations